
Encore Medical, Inc.
Issue Size
$15.00M
Price Range
$5.00
Shares
9.74M o/s · 3M offered
Listing Price
$5.00
Sector
Healthcare
About
Encore Medical, Inc.
Encore Medical is a structural heart device company dedicated to the transcatheter closure of certain cardiac defects.We develop, manufacture, and market septal occlusion products, which are small, implantable devices delivered through a catheter inserted into a major blood vessel to permanently repair certain cardiac defects.
Our devices include patented technology that has been in use extensively outside of the U.S.
Procedures are performed in a cardiac catheterization lab and reduce the need for open heart surgery or a lifetime of drug therapy, which are currently the primary alternative methods for treating these defects.
We have developed devices capable of providing effective, nonsurgical methods of correcting a variety of cardiac defects in both adults and children.
Encore Medical, Inc. Overview
Ticker, listing venue and issuer profile
Offer & Key Dates
Pricing terms and IPO milestones
Valuation & Multiples
Key valuation ratios and metrics
Financial Health
Balance sheet strength and liquidity
Profitability & Returns
Margins and return on capital
Financial Highlights
Historical financial performance
SEC Filings
Official documents from SEC EDGAR
| Form | Filing Date | Document |
|---|---|---|
| FWP | Apr 9, 2026 | Free Writing Prospectus |
| S-1/A | Apr 6, 2026 | [Amend] General form for registration of securities under the Securities Act of 1933 |
| FWP | Apr 3, 2026 | Free Writing Prospectus |
| FWP | Mar 25, 2026 | Free Writing Prospectus |
| S-1/A | Mar 24, 2026 | [Amend] General form for registration of securities under the Securities Act of 1933 |
| S-1/A | Mar 3, 2026 | [Amend] General form for registration of securities under the Securities Act of 1933 |
| S-1/A | Dec 30, 2025 | [Amend] General form for registration of securities under the Securities Act of 1933 |
| S-1 | Sep 15, 2025 | General form for registration of securities under the Securities Act of 1933 |
| D | May 3, 2022 | Notice of Exempt Offering of Securities |
| D | Dec 28, 2020 | Notice of Exempt Offering of Securities |
Company Info
Contact and headquarters details
Leadership
Key executives and officers
Joseph A. Marino
Chairman of the Board of Directors, President and Chief Executive Officer
Peter M. Buonomo
Senior Vice President, Director
Scott S. Robinson
Treasurer
Timothy G. Laske, PhD
Director
Christopher J. Turnbull
Director
Todd C. Johnson
Director